AVDL Fundamental Analysis - AVADEL PHARMACEUTICALS

Fundamental Rating

AVDL gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. AVDL is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. AVDL is not priced too expensively while it is growing strongly. Keep and eye on this one!

Quickly go to:

1. Profitability

1.1 Basic Checks

AVDL had negative earnings in the past year.

In the past year AVDL had a positive cash flow from operations.

AVDL had negative earnings in 4 of the past 5 years.

AVDL had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -1.56%, AVDL is in the better half of the industry, outperforming 77.04% of the companies in the same industry.

AVDL has a Return On Equity of -3.22%. This is in the better half of the industry: AVDL outperforms 78.57% of its industry peers.

Looking at the Return On Invested Capital, with a value of 1.37%, AVDL is in the better half of the industry, outperforming 78.57% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-1.56%
ROE	-3.22%
ROIC	1.37%

ROA(3y)-76.86%

ROA(5y)-51.92%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

AVDL has a Operating Margin of 1.02%. This is in the better half of the industry: AVDL outperforms 78.06% of its industry peers.

Looking at the Gross Margin, with a value of 89.64%, AVDL belongs to the top of the industry, outperforming 92.35% of the companies in the same industry.

AVDL's Gross Margin has improved in the last couple of years.

		Industry Rank	Sector Rank
OM	1.02%
PM (TTM)	N/A
GM	89.64%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5Y2.73%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), AVDL is destroying value.

Compared to 1 year ago, AVDL has more shares outstanding

The number of shares outstanding for AVDL has been increased compared to 5 years ago.

AVDL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

An Altman-Z score of 3.86 indicates that AVDL is not in any danger for bankruptcy at the moment.

The Altman-Z score of AVDL (3.86) is better than 76.02% of its industry peers.

There is no outstanding debt for AVDL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	0
Altman-Z	3.86

ROIC/WACC0.18

WACC7.58%

2.3 Liquidity

AVDL has a Current Ratio of 2.79. This indicates that AVDL is financially healthy and has no problem in meeting its short term obligations.

AVDL has a Current ratio of 2.79. This is comparable to the rest of the industry: AVDL outperforms 53.57% of its industry peers.

A Quick Ratio of 2.38 indicates that AVDL has no problem at all paying its short term obligations.

Looking at the Quick ratio, with a value of 2.38, AVDL is in line with its industry, outperforming 48.47% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	2.79
Quick Ratio	2.38

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

AVDL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 97.37%, which is quite impressive.

AVDL shows a strong growth in Revenue. In the last year, the Revenue has grown by 132.35%.

The Revenue has been growing by 23.35% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)97.37%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%171.43%

Revenue 1Y (TTM)132.35%

Revenue growth 3YN/A

Revenue growth 5Y23.35%

Sales Q2Q%64.15%

3.2 Future

The Earnings Per Share is expected to grow by 46.24% on average over the next years. This is a very strong growth

The Revenue is expected to grow by 23.80% on average over the next years. This is a very strong growth

EPS Next Y144.24%

EPS Next 2Y87.13%

EPS Next 3Y62.83%

EPS Next 5Y46.24%

Revenue Next Year61.36%

Revenue Next 2Y45.28%

Revenue Next 3Y36.93%

Revenue Next 5Y23.8%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

AVDL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

With a Price/Forward Earnings ratio of 17.93, AVDL is valued on the expensive side.

Based on the Price/Forward Earnings ratio, AVDL is valued a bit cheaper than 77.04% of the companies in the same industry.

When comparing the Price/Forward Earnings ratio of AVDL to the average of the S&P500 Index (22.57), we can say AVDL is valued slightly cheaper.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	17.93

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, AVDL is valued a bit cheaper than 76.02% of the companies in the same industry.

Based on the Price/Free Cash Flow ratio, AVDL is valued a bit cheaper than the industry average as 75.51% of the companies are valued more expensively.

		Industry Rank	Sector Rank
P/FCF	240.76
EV/EBITDA	199.55

4.3 Compensation for Growth

AVDL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

A more expensive valuation may be justified as AVDL's earnings are expected to grow with 62.83% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y87.13%

EPS Next 3Y62.83%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for AVDL!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

AVADEL PHARMACEUTICALS

NASDAQ:AVDL (10/10/2025, 9:11:01 PM)

After market: 13.8 -0.2 (-1.43%)

-0.2 (-1.41%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)08-07 2025-08-07/bmo

Earnings (Next)11-05 2025-11-05/bmo

Inst Owners85.64%

Inst Owner Change-0.01%

Ins Owners4.89%

Ins Owner Change1.1%

Market Cap1.27B

Analysts82.5

Price Target20.6 (47.14%)

Short Float %12.12%

Short Ratio8.06

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)144.64%

Min EPS beat(2)31.2%

Max EPS beat(2)258.07%

EPS beat(4)3

Avg EPS beat(4)78.96%

Min EPS beat(4)-20.15%

Max EPS beat(4)258.07%

EPS beat(8)4

Avg EPS beat(8)33.56%

EPS beat(12)4

Avg EPS beat(12)3.14%

EPS beat(16)6

Avg EPS beat(16)-5.8%

Revenue beat(2)2

Avg Revenue beat(2)5.07%

Min Revenue beat(2)1.52%

Max Revenue beat(2)8.61%

Revenue beat(4)3

Avg Revenue beat(4)2.45%

Min Revenue beat(4)-1.22%

Max Revenue beat(4)8.61%

Revenue beat(8)7

Avg Revenue beat(8)7.62%

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)5.62%

PT rev (3m)15.8%

EPS NQ rev (1m)-2.35%

EPS NQ rev (3m)-36.26%

EPS NY rev (1m)-4.88%

EPS NY rev (3m)0.57%

Revenue NQ rev (1m)-0.16%

Revenue NQ rev (3m)4.19%

Revenue NY rev (1m)-0.21%

Revenue NY rev (3m)4.69%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	17.93
P/S	5.74
P/FCF	240.76
P/OCF	232.76
P/B	13.98
P/tB	17.17
EV/EBITDA	199.55

EPS(TTM)-0.03

EYN/A

EPS(NY)0.78

Fwd EY5.58%

FCF(TTM)0.06

FCFY0.42%

OCF(TTM)0.06

OCFY0.43%

SpS2.44

BVpS1

TBVpS0.82

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-1.56%
ROE	-3.22%
ROCE	1.74%
ROIC	1.37%
ROICexc	3.68%
ROICexgc	5.63%
OM	1.02%
PM (TTM)	N/A
GM	89.64%
FCFM	2.38%

ROA(3y)-76.86%

ROA(5y)-51.92%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5Y2.73%

F-Score5

Asset Turnover1.18

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	0
Debt/EBITDA	0
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	0.24
Cash Conversion	93.05%
Profit Quality	N/A
Current Ratio	2.79
Quick Ratio	2.38
Altman-Z	3.86

F-Score5

WACC7.58%

ROIC/WACC0.18

Cap/Depr(3y)15.99%

Cap/Depr(5y)11.39%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)97.37%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%171.43%

EPS Next Y144.24%

EPS Next 2Y87.13%

EPS Next 3Y62.83%

EPS Next 5Y46.24%

Revenue 1Y (TTM)132.35%

Revenue growth 3YN/A

Revenue growth 5Y23.35%

Sales Q2Q%64.15%

Revenue Next Year61.36%

Revenue Next 2Y45.28%

Revenue Next 3Y36.93%

Revenue Next 5Y23.8%

EBIT growth 1Y102.29%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year180.96%

EBIT Next 3Y93.78%

EBIT Next 5Y44.74%

FCF growth 1Y106.19%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y106.45%

OCF growth 3YN/A

OCF growth 5YN/A

AVADEL PHARMACEUTICALS (AVDL) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens